drugset / Trial / NCT02658162
A Study on SANGUINATE™ for the Reduction of Delayed Graft Function in Kidney Transplant Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
Safety and efficacy study of SANGUINATE on reduction of delayed graft function (DGF) in patients who will be recipients of a donation after brain death (DBD) donor kidney.
Timeline
- Start
- 2016-02
- Primary completion
- 2018-10
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | pegylated carboxyhemoglobin bovine | Protein / enzyme biologic | 320 mg/kg | — |